Comparison of diagnostic and prognostic performance of two assays measuring thymidine kinase 1 activity in serum of breast cancer patients

  title={Comparison of diagnostic and prognostic performance of two assays measuring thymidine kinase 1 activity in serum of breast cancer patients},
  author={Benjamin Nisman and Tanir M. Allweis and Luna Kadouri and Bela Mali and Tamar Hamburger and Mario Baras and Simon Gronowitz and Tamar Peretz},
  journal={Clinical Chemistry and Laboratory Medicine (CCLM)},
  pages={439 - 447}
Abstract Background: We compared two recently developed immunoassays for serum thymidine kinase 1 (TK1) activity: one manual assay (DiviTum, Biovica®) and one fully automated assay (Liaison, Diasorin®). Methods: The study included 368 women: 149 healthy blood donors (control), 59 patients with benign breast disease (BBD) and 160 patients with primary breast cancer (BC). Results: A regression analysis of the Liaison (y) and DiviTum (x) assays for all three groups yielded the equation y=3.93+0… 

Figures and Tables from this paper

Serum Concentration of Thymidine Kinase 1 (TK1) as a Tumor Marker in Soft Tissue Sarcomas

TK1 has limited use as a tumor marker in localized STS, and there is no association between increased preoperative TK1 and age, sex, tumor size, grade, and the presence of vascular invasion or necrosis.

A clinical evaluation of the TK 210 ELISA in sera from breast cancer patients demonstrates high sensitivity and specificity in all stages of disease

The first clinical results with the newly developed TK 210 ELISA from AroCell AB strongly suggests that it can provide independent and complementary information for patients with breast cancer.

Serum Thymidine Kinase 1 Activity in the Prognosis and Monitoring of Chemotherapy in Lung Cancer Patients: A Brief Report

  • B. NismanH. Nechushtan T. Peretz
  • Medicine, Biology
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • 2014
Elevated pretreatment serum TK1 activity was an independent, adverse prognostic factor, based on survival, in the two main histological types of LC.

Serum Thymidine Kinase Activity: Analytical Performance, Age-Related Reference Ranges and Validation in Chronic Lymphocytic Leukemia

In the healthy, serum TK1 activity does not differ in the two sexes but declines significantly with age, and use of age-related reference ranges is warranted, especially when evaluating CLL patients who generally belong to the elderly age group.

Breast and prostate cancer patients differ significantly in their serum Thymidine kinase 1 (TK1) specific activities compared with those hematological malignancies and blood donors: implications of using serum TK1 as a biomarker

There are differences in the specific activities and the subunit compositions of STK1 in hematological malignancies compared with breast and prostate cancer, and this fact has several important implications for the use ofSTK1 as a tumor biomarker.

Diagnostic implications of the molecular forms and levels of serum thymidine kinase 1 in different canine malignancies

Overall, the results demonstrate that TK1 protein assays provide valuable diagnostic information in a variety of canine malignancies.

Evaluation of serum thymidine kinase 1 activity as a biomarker for treatment effectiveness and prediction of relapse in dogs with non‐Hodgkin lymphoma

Monitor sTK1 activity as a biomarker for treatment response and early detection of relapse in dogs with lymphoma could help to detect complete responders and early disease progression in dogsWith lymphoma.

Serum thymidine kinase activity compared with CA 15-3 in locally advanced and metastatic breast cancer within a randomized trial

Results suggest that TK1 activity measured by DiviTum™ predicted therapy response, PFS and OS in loco regional inoperable or disseminated breast cancer, and this factor is a useful serum marker.

Preoperative Serum Thymidine Kinase Activity as Novel Monitoring, Prognostic, and Predictive Biomarker in Pancreatic Cancer

Pancreatic ductal adenocarcinomas reveal a significant increase in S-TK activity, which is associated with overall survival, especially in early tumor stages, and may be a useful parameter for monitoring nTx efficacy.



Serum thymidine kinase 1 activity in breast cancer.

Elevated serum TK1 is an important risk factor indicating a high proliferation potential of tumors at the time of excision, and was found to be an independent prognostic factor for RFS.

Elevated serum thymidine kinase 1 predicts risk of pre/early cancerous progression.

Serological TK1 may be a reliable marker for risk assessment of pre/early cancerous progression of breast and prostate hyperplasia and related diseases.

The use of serum deoxythymidine kinase as a prognostic marker, and in the monitoring of patients with non-Hodgkin's lymphoma.

It is concluded that s-dTk could be used both as a prognostic marker and to monitor the effect of therapy in NHL patients.

Serum deoxythymidine kinase gives prognostic information in chronic lymphocytic leukemia

It is concluded that S‐TK could be used as a prognostic marker for the individual CLL patient and seems to be useful for longitudinal follow‐up studies of disease status, both in indolent disease and in progressive disease during treatment.

Sensitive nonradiometric method for determining thymidine kinase 1 activity.

The TK1 enzyme-labeled immunoassay uses a stable substrate, is precise, appears to be accurate, and is resistant to interferences and may provide a practical tool in the management of hematologic malignancies.

Serum thymidine kinase in monoclonal gammopathies. A prospective study

It is indicated that TK has clinical and prognostic relevance in monoclonal gammopathies, and additional investigations are warranted to determine whether it is a useful tool for the clinical evaluation, staging, and follow‐up of patients with MM.

Serum tumour markers in human prostatic carcinoma. The value of a marker panel for prognostic information.

In this study neopterin was found to be most closely related to the clinical course followed by tumour grade, thymidine kinase and PSA, and when all these four variables were in the equation no other parameter added any information of statistical significance.

Thymidine kinase in breast cancer.

Serum thymidine kinase reflects stage of disease in breast cancer and serial thymazine kinase levels in patients with systemic breast cancer reflected response to systemic therapy.

Application of an in vitro assay for serum thymidine kinase: Results on viral disease and malignancies in humans

The TK activity in sera from patients with both mononucleosis and tumor disease was characterized by electrophoresis and by its ability to utilize cytidine triphosphate as the phosphate donor, and showed that the serum TK has the same properties as the human cytosolar TK1, except in connection with varicella.